{
      "Synthesis and preliminary pharmacological investigations of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine derivatives as potential atypical antipsychotic agents in mice .|In research towards the development of new atypical antipsychotic agents , one strategy is that the dopaminergic system can be modulated through manipulation of the serotonergic system .|The synthesis and preliminary pharmacological evaluation of a series of potential atypical antipsychotic agents based on the structure of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine ( 7 ) is described .|Compound 7e , 5 - { 2 - [ 4 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazinyl ] ethyl } - 2 , 3 - dihy dro - 1H - indol - 2 - one , from this series showed significant affinities at the 5 - HT1A and 5 - HT2A receptors and moderate affinity at the D2 receptor .|7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature .": " Here are the relationships identified in the prompt:\n\n[[\"one strategy\",\"is that\",\"the dopaminergic system can be modulated through manipulation of the serotonergic system\"],[\"series\",\"based on the structure of\",\"1-(1, 2-dihydro-2-acenaphthylenyl)piperazine (7)\"],[\"Compound 7e\",\"showed\",\"significant affinities at the 5-HT1A and 5-HT2A receptors and moderate affinity at the D2 receptor\"],[\"Compound 7e\",\"exhibits\",\"a high reversal of catalepsy induced by haloperidol\"]]",
      "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts .|Adenosine triphosphate ( ATP ) and sodium nitroprusside ( SNP ) are administered to patients to induce and control hypotension during anesthesia .|SNP is authorized for clinical use in USA and UK , and ATP is clinically used in other countries such as Japan .|We investigated how these two drugs act on the cardiovascular systems of 20 dogs whose hearts had been denervated by a procedure we had devised .|ATP ( 10 dogs ) or SNP ( 10 dogs ) was administered to reduce mean arterial pressure by 30 % to 70 % of control .|Before , during and after induced hypotension , we measured major cardiovascular parameters .|Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure ( p less than 0 . 001 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 001 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , total body oxygen consumption ( p less than 0 . 05 ) , and heart rate ( p less than 0 . 001 ) ; all these variables returned normal within 30 min after ATP was stopped .|Cardiac output did not change .|During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure ( p less than 0 . 01 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 01 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , and oxygen content difference between arterial and mixed venous blood ( p less than 0 . 05 ) , while heart rate ( p less than 0 . 001 ) and cardiac output ( p less than 0 . 05 ) were increased .|Recoveries of heart rate and left ventricular end - diastolic pressure were not shown within 60 min after SNP had been stopped .|Both ATP and SNP should act on the pacemaker tissue of the heart .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"Adenosine triphosphate ( ATP )\", \"administered to\", \"patients\"], [\"sodium nitroprusside ( SNP )\", \"administered to\", \"patients\"], [\"Adenosine triphosphate ( ATP )\", \"is clinically used in\", \"other countries such as Japan\"], [\"sodium nitroprusside ( SNP )\", \"is authorized for clinical use in\", \"USA\"], [\"sodium nitroprusside ( SNP )\", \"is authorized for clinical use in\", \"UK\"], [\"Adenosine triphosphate ( ATP )\", \"act on\", \"cardiovascular systems of 20 dogs\"], [\"sodium nitroprusside ( SNP )\", \"act on\", \"cardiovascular systems of 20 dogs\"], [\"Adenosine triphosphate ( ATP )\", \"administered to reduce\", \"mean arterial pressure\"], [\"sodium nitroprusside ( SNP )\", \"administered to reduce\", \"mean arterial pressure\"], [\"Adenosine triphosphate ( ATP )\", \"accompanied by decreases in\", \"mean pulmonary arterial pressure\"], [\"Adenosine triphosphate ( ATP )\", \"accompanied by decreases in\", \"central venous pressure\"], [\"Adenosine triphosphate ( ATP )\", \"accompanied by decreases in\", \"left ventricular end - diastolic pressure\"], [\"Adenosine triphosphate ( ATP )\", \"accompanied by decreases in\", \"total peripheral resistance\"], [\"Adenosine triphosphate ( ATP )\", \"accompanied by decreases in\", \"rate pressure product\"], [\"Adenosine triphosphate ( ATP )\", \"accompanied by decreases in\", \"total body oxygen consumption\"], [\"Adenosine triphosphate ( ATP )\", \"accompanied by decreases in\", \"heart rate\"], [\"sodium nitroprusside ( SNP )\", \"accompanied by decreases in\", \"mean pulmonary arterial pressure\"], [\"sodium nitroprusside ( SNP )\", \"accompanied by decreases in\", \"central venous pressure\"], [\"sodium nitroprusside ( SNP )\", \"accompanied by decreases in\", \"left ventricular end - diastolic pressure\"], [\"sodium nitroprusside ( SNP )\", \"accompanied by decreases in\", \"total peripheral resistance\"], [\"sodium nitroprusside ( SNP )\", \"accompanied by decreases in\", \"rate pressure product\"], [\"sodium nitroprusside ( SNP )\", \"accompanied by decreases in\", \"oxygen content difference between arterial and mixed venous blood\"], [\"sodium nitroprusside ( SNP )\", \"accompanied by increases in\", \"heart rate\"], [\"sodium nitroprusside ( SNP )\", \"accompanied by increases in\", \"cardiac output\"], [\"Adenosine triphosphate ( ATP )\", \"should act on\", \"pacemaker tissue of the heart\"], [\"sodium nitroprusside ( SNP )\", \"should act on\", \"pacemaker tissue of the heart\"]]",
      "Histamine antagonists and d - tubocurarine - induced hypotension in cardiac surgical patients .|Hemodynamic effects and histamine release by bolus injection of 0 . 35 mg / kg of d - tubocurarine were studied in 24 patients .|H1 - and H2 - histamine antagonists or placebo were given before dosing with d - tubocurarine in a randomized double - blind fashion to four groups : group 1 - - placebo ; group 2 - - cimetidine , 4 mg / kg , plus placebo ; group 3 - - chlorpheniramine , 0 . 1 mg / kg , plus placebo ; and group 4 - - cimetidine plus chlorpheniramine .|Histamine release occurred in most patients , the highest level 2 minutes after d - tubocurarine dosing .|Group 1 had a moderate negative correlation between plasma histamine change and systemic vascular resistance ( r = 0 . 58 ; P less than 0 . 05 ) not present in group 4 .|Prior dosing with antagonists partially prevented the fall in systemic vascular resistance .|These data demonstrate that the hemodynamic changes associated with d - tubocurarine dosing are only partially explained by histamine release .|Thus prior dosing with H1 - and H2 - antagonists provides only partial protection .": " Based on the prompt, I have extracted the following entity relations:\n\n[[\"Histamine antagonists\", \"and\", \"d - tubocurarine - induced hypotension\"], \n[\"Hemodynamic effects\", \"and\", \"histamine release\"], \n[\"bolus injection\", \"of\", \"0.35 mg/kg of d - tubocurarine\"], \n[\"24 patients\", \"\", \"\"],\n[\"H1 - and H2 - histamine antagonists\", \"or\", \"placebo\"], \n[\"d - tubocurarine\", \"in\", \"a randomized double - blind fashion\"], \n[\"four groups\", \"\", \"\"],\n[\"group 1\", \"\", \"placebo\"],\n[\"group 2\", \"\", \"cimetidine, 4 mg/kg, plus placebo\"],\n[\"group 3\", \"\", \"chlorpheniramine, 0.1 mg/kg, plus placebo\"],  \n[\"group 4\", \"\", \"cimetidine plus chlorpheniramine\"],\n[\"Histamine release\", \"occurred in\", \"most patients\"],\n[\"\", \"the highest level\", \"2 minutes after d - tubocurarine dosing\"],\n[\"Group 1\", \"had\", \"a moderate negative correlation between plasma histamine change and systemic vascular resistance\"], \n[\"systemic vascular resistance\", \"\", \"( r = 0 . 58 ; P less than 0 . 05 )\"], \n[\"group 4\", \"\", \"\"],\n[\"Prior dosing\", \"with\", \"antagonists\"], \n[\"the fall\", \"in\", \"systemic vascular resistance\"],\n[\"These data\", \"demonstrate that\", \"the hemodynamic changes associated with d - tubocurarine dosing\"],\n[\"the hemodynamic changes\", \"are\", \"only partially explained by histamine release\"],\n[\"prior dosing\", \"with\", \"H1 - and H2 - antagonists\"], \n[\"only partial protection\", \"\", \"\"]]",
      "Cholecystokinin - octapeptide restored morphine - induced hippocampal long - term potentiation impairment in rats .|Cholecystokinin - octapeptide ( CCK - 8 ) , which is a typical brain - gut peptide , exerts a wide range of biological activities on the central nervous system .|We have previously reported that CCK - 8 significantly alleviated morphine - induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine - treated animals .|Here , we investigated the effects of CCK - 8 on long - term potentiation ( LTP ) in the lateral perforant path ( LPP ) - granule cell synapse of rat dentate gyrus ( DG ) in acute saline or morphine - treated rats .|Population spikes ( PS ) , which were evoked by stimulation of the LPP , were recorded in the DG region .|Acute morphine ( 30mg / kg , s . c . ) treatment significantly attenuated hippocampal LTP and CCK - 8 ( 1ug , i . c . v . ) restored the amplitude of PS that was attenuated by morphine injection .|Furthermore , microinjection of CCK - 8 ( 0 . 1 and 1ug , i . c . v . ) also significantly augmented hippocampal LTP in saline - treated ( 1ml / kg , s . c . ) rats .|Pre - treatment of the CCK2 receptor antagonist L - 365 , 260 ( 10ug , i . c . v ) reversed the effects of CCK - 8 , but the CCK1 receptor antagonist L - 364 , 718 ( 10ug , i . c . v ) did not .|The present results demonstrate that CCK - 8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK - 8 on morphine - induced memory impairment .": " Here are the extracted relationships from the prompt:\n\n[[\"Cholecystokinin-octapeptide\", \"restored\", \"morphine - induced hippocampal long - term potentiation impairment in rats\"], [\"Cholecystokinin - octapeptide (CCK-8)\", \"is a\", \"typical brain - gut peptide\"], [\"Cholecystokinin - octapeptide (CCK-8)\", \"exerts\", \"wide range of biological activities on the central nervous system\"], [\"We\", \"have previously reported\", \"that CCK-8 significantly alleviated morphine - induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine - treated animals\"], [\"We\", \"investigated\", \"effects of CCK-8 on long - term potentiation (LTP) in the lateral perforant path (LPP) - granule cell synapse of rat dentate gyrus (DG) in acute saline or morphine - treated rats\"], [\"Population spikes (PS)\", \"were evoked by\", \"stimulation of the LPP\"], [\"Population spikes (PS)\", \"were recorded\", \"in the DG region\"], [\"Acute morphine (30mg/kg, s.c.)\", \"significantly attenuated\", \"hippocampal LTP\"], [\"Cholecystokinin-octapeptide (CCK-8)\", \"restored\", \" amplitude of PS that was attenuated by morphine injection\"], [\"microinjection of Cholecystokinin-octapeptide (CCK-8)\", \"significantly augmented\", \"hippocampal LTP in saline - treated (1ml/kg, s.c.) rats\"], [\"Pre - treatment of the CCK2 receptor antagonist L-365, 260\", \"reversed\", \"effects of CCK-8\"], [\"the CCK1 receptor antagonist L-364, 718 \", \"did not\", \"reverse effects of CCK-8\"], [\"The present results\", \"demonstrate\", \"that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors\"], [\"The present results\", \"suggest\", \"ameliorative function of CCK-8 on morphine - induced memory impairment\"]]",
      "Acute neurologic dysfunction after high - dose etoposide therapy for malignant glioma .|Etoposide ( VP - 16 - 213 ) has been used in the treatment of many solid tumors and hematologic malignancies .|When used in high doses and in conjunction with autologous bone marrow transplantation , this agent has activity against several treatment - resistant cancers including malignant glioma .|In six of eight patients ( 75 % ) who we treated for recurrent or resistant glioma , sudden severe neurologic deterioration occurred .|This developed a median of 9 days after initiation of high - dose etoposide therapy .|Significant clinical manifestations have included confusion , papilledema , somnolence , exacerbation of motor deficits , and sharp increase in seizure activity .|These abnormalities resolved rapidly after initiation of high - dose intravenous dexamethasone therapy .|In all patients , computerized tomographic ( CT ) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans .|This complication appears to represent a significant new toxicity of high - dose etoposide therapy for malignant glioma .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"Etoposide (VP-16-213)\", \"has been used in the treatment of\", \"many solid tumors and hematologic malignancies\"], [\"Etoposide (VP-16-213)\", \"has activity against\", \"several treatment-resistant cancers including malignant glioma\"], [\"high doses and in conjunction with autologous bone marrow transplantation\", \"increases activity of\", \"Etoposide (VP-16-213)\"], [\"high - dose etoposide therapy\", \"causes\", \"sudden severe neurologic deterioration\"], [\"high - dose etoposide therapy\", \"causes\", \"confusion\"], [\"high - dose etoposide therapy\", \"causes\", \"papilledema\"], [\"high - dose etoposide therapy\", \"causes\", \"somnolence\"], [\"high - dose etoposide therapy\", \"exacerbates\", \"motor deficits\"], [\"high - dose etoposide therapy\", \"increases\", \"seizure activity\"], [\"high-dose intravenous dexamethasone therapy\", \"resolves\", \"abnormalities from high-dose etoposide therapy\"], [\"computerized tomographic (CT) brain scans\", \"showed stability in\", \"tumor size and peritumor edema\"]]",
      "Increased anxiogenic effects of caffeine in panic disorders .|The effects of oral administration of caffeine ( 10 mg / kg ) on behavioral ratings , somatic symptoms , blood pressure and plasma levels of 3 - methoxy - 4 - hydroxyphenethyleneglycol ( MHPG ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM - III criteria for agoraphobia with panic attacks or panic disorder .|Caffeine produced significantly greater increases in subject - rated anxiety , nervousness , fear , nausea , palpitations , restlessness , and tremors in the patients compared with healthy subjects .|In the patients , but not the healthy subjects , these symptoms were significantly correlated with plasma caffeine levels .|Seventy - one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks .|Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients .|Caffeine increased plasma cortisol levels equally in the patient and healthy groups .|Because caffeine is an adenosine receptor antagonist , these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine .|Patients with anxiety disorders may benefit by avoiding caffeine - containing foods and beverages .": " Based on the prompt, here are the extracted entity relationships:\n\n[[\"caffeine\", \"has\", \"anxiogenic effects\"], [\"caffeine\", \"administered\", \"orally\"], [\"caffeine dosage\", \"is\", \"10 mg/kg\"], [\"anxiogenic effects of caffeine\", \"increased in\", \"panic disorders\"], [\"behavioral effects of caffeine\", \"similar to\", \"those experienced during panic attacks\"], [\"caffeine\", \"is\", \"adenosine receptor antagonist\"], [\"caffeine\", \"did not alter\", \"plasma MHPG levels\"], [\"caffeine\", \"increased\", \"plasma cortisol levels\"], [\"caffeine\", \"increased\", \"subject-rated anxiety\"], [\"caffeine\", \"increased\", \"nervousness\"], [\"caffeine\", \"increased\", \"fear\"], [\"caffeine\", \"increased\", \"nausea\"], [\"caffeine\", \"increased\", \"palpitations\"], [\"caffeine\", \"increased\", \"restlessness\"], [\"caffeine\", \"increased\", \"tremors\"], [\"these symptoms\", \"correlated with\", \"plasma caffeine levels\"], [\"some panic disorder patients\", \"may have abnormalities in\", \"neuronal systems involving adenosine\"], [\"patients with anxiety disorders\", \"may benefit by avoiding\", \"caffeine-containing foods and beverages\"]]",
      "In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin - induced nephrotoxicity : protection by erdosteine .|The aims of this study were to examine vancomycin ( VCM ) - induced oxidative stress that promotes production of reactive oxygen species ( ROS ) and to investigate the role of erdosteine , an expectorant agent , which has also antioxidant properties , on kidney tissue against the possible VCM - induced renal impairment in rats .|Rats were divided into three groups : sham , VCM and VCM plus erdosteine .|VCM was administrated intraperitoneally ( i . p . ) with 200mgkg ( - 1 ) twice daily for 7 days .|Erdosteine was administered orally .|VCM administration to control rats significantly increased renal malondialdehyde ( MDA ) and urinary N - acetyl - beta - d - glucosaminidase ( NAG , a marker of renal tubular injury ) excretion but decreased superoxide dismutase ( SOD ) and catalase ( CAT ) activities .|Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion , and increased SOD activity , but not CAT activity in renal tissue when compared with VCM alone .|Erdosteine showed histopathological protection against VCM - induced nephrotoxicity .|There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , atrophy , desquamation , and necrosis in VCM - treated rats more than those of the control and the erdosteine groups .|Erdosteine caused a marked reduction in the extent of tubular damage .|It is concluded that oxidative tubular damage plays an important role in the VCM - induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM - induced kidney damage both at the biochemical and histological levels .": " Based on the prompt, I have extracted the following entity relations:\n\n[[\"vancomycin\", \"induces\", \"oxidative stress\"], [\"vancomycin\", \"promotes production of\", \"reactive oxygen species (ROS)\"], [\"oxidative stress\", \"plays role in pathogenesis of\", \"vancomycin-induced nephrotoxicity\"], [\"erdosteine\", \"has\", \"antioxidant properties\"], [\"erdosteine\", \"protects\", \"kidney tissue\"], [\"erdosteine\", \"protects against\", \"vancomycin-induced renal impairment\"], [\"rats\", \"divided into\", \"sham group\"], [\"rats\", \"divided into\", \"VCM group\"], [\"rats\", \"divided into\", \"VCM plus erdosteine group\"], [\"vancomycin\", \"administrated intraperitoneally to\", \"rats\"], [\"erdosteine\", \"administered orally to\", \"rats\"], [\"vancomycin administration\", \"increases\", \"renal malondialdehyde (MDA)\"], [\"vancomycin administration\", \"increases\", \"urinary N-acetyl-beta-d-glucosaminidase (NAG) excretion\"], [\"N-acetyl-beta-d-glucosaminidase (NAG)\", \"marker of\", \"renal tubular injury\"], [\"vancomycin administration\", \"decreases\", \"superoxide dismutase (SOD)\"], [\"vancomycin administration\", \"decreases\", \"catalase (CAT)\"], [\"erdosteine administration with vancomycin\", \"decreases\", \"renal malondialdehyde (MDA)\"], [\"erdosteine administration with vancomycin\", \"decreases\", \"urinary N-acetyl-beta-d-glucosaminidase (NAG) excretion\"], [\"erdosteine administration with vancomycin\", \"increases\", \"superoxide dismutase (SOD) activity\"], [\"vancomycin-treated rats\", \"exhibit\", \"dilatation of tubular lumens\"], [\"vancomycin-treated rats\", \"exhibit\", \"extensive epithelial cell vacuolization\"], [\"vancomycin-treated rats\", \"exhibit\", \"atrophy\"], [\"vancomycin-treated rats\", \"exhibit\", \"desquamation\"], [\"vancomycin-treated rats\", \"exhibit\", \"necrosis\"], [\"erdosteine\", \"reduces\", \"extent of tubular damage\"]]",
      "Comparison of laryngeal mask with endotracheal tube for anesthesia in endoscopic sinus surgery .|BACKGROUND : The purpose of this study was to compare surgical conditions , including the amount of intraoperative bleeding as well as intraoperative blood pressure , during functional endoscopic sinus surgery ( FESS ) using flexible reinforced laryngeal mask airway ( FRLMA ) versus endotracheal tube ( ETT ) in maintaining controlled hypotension anesthesia induced by propofol - remifentanil total i . v .|anesthesia ( TIVA ) .|METHODS : Sixty normotensive American Society of Anesthesiologists I - II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol - remifentanil - TIVA were randomly assigned into two groups : group I , FRLMA ; group II , ETT .|Hemorrhage was measured and the visibility of the operative field was evaluated according to a six - point scale .|RESULTS : Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil .|CONCLUSION : In summary , our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS .": " Based on the prompt, I extracted the following entity relationships:\n\n[[\"laryngeal mask\", \"compared with\", \"endotracheal tube\"], [\"laryngeal mask\", \"used for\", \"anesthesia\"], [\"laryngeal mask\", \"used during\", \"endoscopic sinus surgery\"], [\"endoscopic sinus surgery\", \"performed under\", \"controlled hypotension anesthesia\"], [\"controlled hypotension anesthesia\", \"induced by\", \"propofol-remifentanil total i.v. anesthesia (TIVA)\"], [\"flexible reinforced laryngeal mask airway (FRLMA)\", \"compared to\", \" endotracheal tube\"], [\"FRLMA\", \"provides\", \"better surgical conditions\"], [\"FRLMA\", \"results in\", \"lower blood loss\"], [\"FRLMA\", \"allows\", \"induced hypotension with low doses of remifentanil during TIVA\"]]",
      "Paclitaxel 3 - hour infusion given alone and combined with carboplatin : preliminary results of dose - escalation trials .|Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) by 3 - hour infusion was combined with carboplatin in a phase I / II study directed to patients with non - small cell lung cancer .|Carboplatin was given at a fixed target area under the concentration - time curve of 6 . 0 by the Calvert formula , whereas paclitaxel was escalated in patient cohorts from 150 mg / m2 ( dose level I ) to 175 , 200 , 225 , and 250 mg / m2 .|The 225 mg / m2 level was expanded for the phase II study since the highest level achieved ( 250 mg / m2 ) required modification because of nonhematologic toxicities ( arthralgia and sensory neuropathy ) .|Therapeutic effects were noted at all dose levels , with objective responses in 17 ( two complete and 15 partial regressions ) of 41 previously untreated patients .|Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels .|Carboplatin did not appear to add to the hematologic toxicities observed , and the paclitaxel / carboplatin combination could be dosed every 3 weeks .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"Paclitaxel\", \"given as\", \"3 - hour infusion\"], [\"Paclitaxel\", \"combined with\", \"carboplatin\"], [\"Carboplatin\", \"given at\", \"fixed target area under the concentration - time curve of 6.0\"], [\"Paclitaxel\", \"escalated from\", \"150 mg / m2\"], [\"Paclitaxel\", \"escalated to\", \"175 mg / m2\"], [\"Paclitaxel\", \"escalated to\", \"200 mg / m2\"], [\"Paclitaxel\", \"escalated to\", \"225 mg / m2\"], [\"Paclitaxel\", \"escalated to\", \"250 mg / m2\"], [\"225 mg / m2 level\", \"expanded for\", \"phase II study\"], [\"250 mg / m2\", \"required modification because of\", \"nonhematologic toxicities\"], [\"nonhematologic toxicities\", \"included\", \"arthralgia\"], [\"nonhematologic toxicities\", \"included\", \"sensory neuropathy\"], [\"Therapeutic effects\", \"noted at\", \"all dose levels\"], [\"Objective responses\", \"in\", \"17 of 41 previously untreated patients\"], [\"Toxicities\", \"compared with\", \"cohort of patients in a phase I trial of paclitaxel alone\"], [\"Carboplatin\", \"did not appear to add to\", \"the hematologic toxicities observed\"], [\"the paclitaxel / carboplatin combination\", \"could be dosed every\", \"3 weeks\"]]",
      "Quinine - induced arrhythmia in a patient with severe malaria .|It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( premature ventricular contraction ) while getting quinine infusion was reported .|A man , 25 years old , was admitted to hospital with high fever , chill , vomiting , jaundice .|The patient was fully conscious , blood pressure 120 / 80 mmHg , pulse rate 100 x / minute , regular .|On admission , laboratory examination showed Plasmodium falciparum ( + + + + ) , total bilirubin 8 . 25 mg / dL , conjugated bilirubin 4 . 36 mg / dL , unconjugated bilirubin 3 . 89 mg / dL , potassium 3 . 52 meq / L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5 % 500 mg / 8 hour .|On the second day the patient had vomitus , diarrhea , tinnitus , loss of hearing .|After 30 hours of quinine infusion the patient felt palpitation and electrocardiography ( ECG ) recording showed premature ventricular contraction ( PVC ) > 5 x / minute , trigemini , constant type - - sinoatrial block , positive U wave .|He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5 % / 24 hour and potassium aspartate tablet .|Quinine infusion was discontinued and changed with sulfate quinine tablets .|Three hours later the patient felt better , the frequency of PVC reduced to 4 - 5 x / minute and on the third day ECG was normal , potassium level was 3 . 34 meq / L .|He was discharged on 7th day in good condition .|Quinine , like quinidine , is a chincona alkaloid that has anti - arrhythmic property , although it also pro - arrhythmic that can cause various arrhythmias , including severe arrhythmia such as multiple PVC .|Administration of parenteral quinine must be done carefully and with good observation because of its pro - arrhythmic effect , especially in older patients who have heart diseases or patients with electrolyte disorder ( hypokalemia ) which frequently occurs due to vomiting and or diarrhea in malaria cases .": " Based on the prompt, I have extracted the following entity relationships:\n\n[[\"severe malaria patient\", \"presented with\", \"arrhythmia (premature ventricular contraction)\"], [\"arrhythmia (premature ventricular contraction)\", \"while getting\", \"quinine infusion\"], [\"A man, 25 years old\", \"was admitted to\", \"hospital\"], [\"man, 25 years old\", \"had\", \"high fever\"], [\"man, 25 years old\", \"had\", \"chill\"], [\"man, 25 years old\", \"had\", \"vomiting\"], [\"man, 25 years old\", \"had\", \"jaundice\"], [\"patient\", \"was\", \"fully conscious\"], [\"patient\", \"had\", \"blood pressure 120/80 mmHg\"], [\"patient\", \"had\", \"pulse rate 100 x/minute\"], [\"patient\", \"had\", \"regular\" , \"pulse rate\"], [\"laboratory examination\", \"showed\", \"Plasmodium falciparum (++++)\"], [\"laboratory examination\", \"showed\", \"total bilirubin 8.25 mg/dL\"], [\"laboratory examination\", \"showed\", \"conjugated bilirubin 4.36 mg/dL\"], [\"laboratory examination\", \"showed\", \"unconjugated bilirubin 3.89 mg/dL\"], [\"laboratory examination\", \"showed\", \"potassium 3.52 meq/L\"], [\"patient\", \"was diagnosed as\", \"severe malaria with jaundice\"], [\"patient\", \"got\", \"quinine infusion\"], [\"patient\", \"had\", \"vomitus\"], [\"patient\", \"had\", \"diarrhea\"], [\"patient\", \"had\", \"tinnitus\"], [\"patient\", \"had\", \"loss of hearing\"], [\"After 30 hours of quinine infusion\", \"the patient felt\", \"palpitation\"], [\"electrocardiography (ECG) recording\", \"showed\", \"premature ventricular contraction (PVC) > 5 x/minute\"], [\"electrocardiography (ECG) recording\", \"showed\", \"trigemini\"], [\"electrocardiography (ECG) recording\", \"showed\", \"constant type -- sinoatrial block\"], [\"electrocardiography (ECG) recording\", \"showed\", \"positive U wave\"], [\"He\", \"was treated with\", \"lidocaine 50 mg intravenously\"], [\"He\", \"was treated with\", \"infusion 1500 mg in dextrose 5%/24 hour\"], [\"He\", \"was treated with\", \"potassium aspartate tablet\"], [\"Quinine infusion\", \"was discontinued\"], [\"Quinine infusion\", \"was changed with\", \"sulfate quinine tablets\"], [\"Three hours later\", \"the patient felt\", \"better\"], [\"the frequency of PVC\", \"reduced to\", \"4-5 x/minute\"], [\"on the third day\", \"ECG was\", \"normal\"], [\"potassium level\", \"was\", \"3.34 meq/L\"], [\"He\", \"was discharged\", \"on 7th day\"], [\"He\", \"was\", \"in good condition\"], [\"Quinine, like quinidine\", \"is\", \"a chincona alkaloid\"], [\"Quinine\", \"has\", \"anti-arrhythmic property\"], [\"it\", \"also\", \"pro-arrhythmic\"], [\"it\", \"can cause\", \"various arrhythmias\"], [\"it\", \"can cause\", \"severe arrhythmia such as multiple PVC\"], [\"Administration of parenteral quinine\", \"must be done\", \"carefully\"], [\"Administration of parenteral quinine\", \"must be done with\", \"good observation\"], [\"its pro-arrhythmic effect\", \"can cause\", \"arrhythmias\"], [\"its pro-arrhythmic effect\", \"especially in\", \"older patients who have heart diseases\"], [\"its pro-arrhythmic effect\", \"especially in\", \"patients with electrolyte disorder (hypokalemia)\"]]",
      "Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU - induced cortical dysplasia .|Cortical dysplasia is a malformation characterized by defects in proliferation , migration and maturation .|This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine - [ 1 , 3 - bis ( 2 - chloroethyl ) - 1 - nitrosoure ] ( BCNU ) and to investigate the effects of exogenous melatonin upon cerebellar BCNU - induced cortical dysplasia , using histological and biochemical analyses .|Pregnant Wistar rats were assigned to five groups : intact - control , saline - control , melatonin - treated , BCNU - exposed and BCNU - exposed plus melatonin .|Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery .|Immuno / histochemistry and electron microscopy were carried out on the offspring cerebellum , and levels of malondialdehyde and superoxide dismutase were determined .|Histopathologically , typical findings were observed in the cerebella from the control groups , but the findings consistent with early embryonic development were noted in BCNU - exposed cortical dysplasia group .|There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU - exposed group , but a decreased immunoreactivity to glial fibrillary acidic protein , synaptophysin and transforming growth factor beta1 was observed , indicating a delayed maturation , and melatonin significantly reversed these changes .|Malondialdehyde level in BCNU - exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group ( P < 0 . 01 ) , while there were no significant differences in the superoxide dismutase levels between these groups .|These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU .": " Here are the relationships I extracted from the prompt:\n\n[[\"Neuroprotective effects of melatonin\", \"upon\", \"the offspring cerebellar cortex in the rat model of BCNU - induced cortical dysplasia\"], [\"Cortical dysplasia\", \"is a\", \"malformation\"], [\"Cortical dysplasia\", \"characterized by\", \"defects in proliferation , migration and maturation\"], [\"This study\", \"was designed to evaluate\", \"the alterations in offspring rat cerebellum induced by maternal exposure to carmustine - [ 1 , 3 - bis ( 2 - chloroethyl ) - 1 - nitrosoure ] ( BCNU )\"], [\"This study\", \"was designed to investigate\", \"the effects of exogenous melatonin upon cerebellar BCNU - induced cortical dysplasia, using histological and biochemical analyses\"], [\"Pregnant Wistar rats\", \"were assigned to\", \"five groups\"], [\"rats\", \"were exposed to\", \"BCNU\"], [\"BCNU\", \"exposed on\", \"embryonic day 15\"], [\"melatonin\", \"was given until\", \"delivery\"], [ \"Immuno / histochemistry and electron microscopy\", \"were carried out on\", \"the offspring cerebellum\"], [\"levels of malondialdehyde and superoxide dismutase\", \"were determined\", null], [\"Histopathologically\", \"were observed\", \"typical findings\"], [\"Histopathologically\", \"were observed\", \"typical findings in the cerebella from the control groups\"], [\"the findings consistent with early embryonic development\", \"were noted\", \"in BCNU - exposed cortical dysplasia group\"], [\"a marked increase in the number of TUNEL positive cells and nestin positive cells\", \"was observed\", \"in BCNU - exposed group\"], [\"a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1\", \"was observed\", null], [\"indicating\", \"a delayed maturation\", null], [\"melatonin\", \"significantly reversed\", \"these changes\"], [\"Malondialdehyde level in BCNU - exposed group\", \"was\", \"higher than those in control groups\"], [\"melatonin\", \"decreased\", \"malondialdehyde levels in BCNU group ( P < 0 . 01 ) \"], [\"There were no significant differences in superoxide dismutase levels\", null, \"between these groups\"], [\"These data\", \"suggest that\", \"exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum\"], [\"melatonin\", \"protects\", \"the cerebellum against the effects of BCNU\"]]",
      "Overexpression of copper / zinc - superoxide dismutase protects from kanamycin - induced hearing loss .|The participation of reactive oxygen species in aminoglycoside - induced ototoxicity has been deduced from observations that aminoglycoside - iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo .|We therefore hypothesized that overexpression of Cu / Zn - superoxide dismutase ( h - SOD1 ) should protect transgenic mice from ototoxicity .|Immunocytochemistry confirmed expression of h - SOD1 in inner ear tissues of transgenic C57BL / 6 - TgN [ SOD1 ] 3Cje mice .|Transgenic and nontransgenic littermates received kanamycin ( 400 mg / kg body weight / day ) for 10 days beginning on day 10 after birth .|Auditory thresholds were tested by evoked auditory brain stem responses at 1 month after birth .|In nontransgenic animals , the threshold in the kanamycin - treated group was 45 - 50 dB higher than in saline - injected controls .|In the transgenic group , kanamycin increased the threshold by only 15 dB over the respective controls .|The effects were similar at 12 and 24 kHz .|The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside - induced ototoxicity .|The results also suggest transgenic animals as suitable models to investigate the underlying mechanisms and possible strategies for prevention .": " Here are the relationships extracted from the prompt:\n\n[[\"Overexpression of copper / zinc - superoxide dismutase\", \"protects from\", \"kanamycin - induced hearing loss\"], [\"reactive oxygen species\", \"involved in\", \"aminoglycoside - induced ototoxicity\"], [\"aminoglycoside - iron complexes\", \"catalyze\", \"formation of superoxide radicals in vitro\"], [\"antioxidants\", \"attenuate\", \"ototoxicity in vivo\"], [\"We\", \"hypothesized\", \"overexpression of Cu / Zn - superoxide dismutase ( h - SOD1 ) should protect transgenic mice from ototoxicity\"], [\"h - SOD1\", \"expressed in\", \"inner ear tissues of transgenic C57BL / 6 - TgN [ SOD1 ] 3Cje mice\"], [\"Transgenic and nontransgenic littermates\", \"received\", \"kanamycin ( 400 mg / kg body weight / day ) for 10 days beginning on day 10 after birth\"], [\"Auditory thresholds\", \"tested by\", \"evoked auditory brain stem responses at 1 month after birth\"], [\"threshold in the kanamycin - treated group\", \"was higher than\", \"in saline - injected controls\"], [\"protection by overexpression of superoxide dismutase\", \"supports\", \"hypothesis that oxidant stress plays a significant role in aminoglycoside - induced ototoxicity\"], [\"transgenic animals\", \"as suitable models to investigate\", \"underlying mechanisms and possible strategies for prevention\"]]",
      "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers : a placebo - controlled trial .|Lamivudine is a novel 2 ' , 3 ' - dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo .|We performed a single - blind , placebo - controlled study to assess its effectiveness and safety in Chinese hepatitis B surface antigen ( HBsAg ) carriers .|Forty - two Chinese HBsAg carriers were randomized to receive placebo ( 6 patients ) or lamivudine orally in dosages of 25 mg , 100 mg , or 300 mg daily ( 12 patients for each dosage ) .|The drug was given for 4 weeks .|The patients were closely monitored clinically , biochemically , and serologically up to 4 weeks after drug treatment .|All 36 patients receiving lamivudine had a decrease in hepatitis B virus ( HBV ) DNA values of > 90 % ( P < . 001 compared with placebo ) .|Although 25 mg of lamivudine was slightly less effective than 100 mg ( P = . 011 ) and 300 mg ( P = . 005 ) , it still induced 94 % suppression of HBV DNA after the fourth week of therapy .|HBV DNA values returned to pretreatment levels within 4 weeks of cessation of therapy .|There was no change in the hepatitis B e antigen status or in aminotransferase levels .|No serious adverse events were observed .|In conclusion , a 4 - week course of lamivudine was safe and effective in suppression of HBV DNA in Chinese HBsAg carriers .|The suppression was > 90 % but reversible .|Studies with long - term lamivudine administration should be performed to determine if prolonged suppression of HBV DNA can be achieved .": " Based on the prompt, I extracted the following entity relationships:\n\n[[\"Lamivudine\", \"is\", \"a novel 2',3'-dideoxy cytosine analogue\"], [\"Lamivudine\", \"has\", \"potent inhibitory effects on hepatitis B virus replication in vitro and in vivo\"], [\"We\", \"performed\", \"a single-blind, placebo-controlled study\"], [\"study\", \"to assess\", \"its effectiveness and safety in Chinese hepatitis B surface antigen (HBsAg) carriers\"], [\"Forty-two Chinese HBsAg carriers\", \"were randomized\", \"to receive placebo or lamivudine orally\"], [\"lamivudine\", \"given\", \"in dosages of 25 mg, 100 mg, or 300 mg daily\"], [\"The drug\", \"was given\", \"for 4 weeks\"], [\"patients\", \"receiving\", \"lamivudine\"], [\"lamivudine\", \"had\", \"a decrease in hepatitis B virus (HBV) DNA values of > 90%\"], [\"25 mg of lamivudine\", \"was\", \"slightly less effective than 100 mg and 300 mg\"], [\"it\", \"still induced\", \"94% suppression of HBV DNA after the fourth week of therapy\"], [\"HBV DNA values\", \"returned\", \"to pretreatment levels within 4 weeks of cessation of therapy\"], [\"There\", \"was\", \"no change in the hepatitis B e antigen status or in aminotransferase levels\"], [\"No serious adverse events\", \"were observed\", null], [\"a 4-week course of lamivudine\", \"was\", \"safe and effective in suppression of HBV DNA in Chinese HBsAg carriers\"], [\"The suppression\", \"was\", \"> 90% but reversible\"], [\"Studies with long-term lamivudine administration\", \"should be performed\", \"to determine if prolonged suppression of HBV DNA can be achieved\"]]"
}